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Abstract
Background: A better understanding of immune response in breast cancer brain metastases (BCBM) may prompt
new preventive and therapeutic strategies.
Methods: Immunohistochemical expression of stromal tumor-infiltrating lymphocytes (TILs: CD4, CD8, CTLA4),
macrophage/microglial cells (CD68), programmed cell death protein 1 receptor (PD-1), programmed cell death
protein 1 receptor ligand (PD-L)1, PD-L2 and glial fibrillary acid protein was assessed in 84 BCBM and their
microenvironment.
Results: Median survival after BCBM excision was 18.3 months (range 0–99). Median number of CD4+, CD8+ TILs
and CD68+ was 49, 69 and 76 per 1 mm2, respectively. PD-L1 and PD-L2 expression in BCBM was present in 53 %
and 36 % of cases, and was not related to BCBM phenotype. PD-1 expression on TILs correlated positively with
CD4+ and CD8+ TILs (r = 0.26 and 0.33), and so did CD68+ (r = 0.23 and 0.27, respectively). In the multivariate
analysis, survival after BCBM excision positively correlated with PD-1 expression on TILs (hazard ratio (HR) = 0.3,
P = 0.003), CD68+ infiltration (HR = 0.2, P < 0.001), brain radiotherapy (HR = 0.1, P < 0.001), endocrine therapy
(HR = 0.1, P < 0.001), and negatively with hormone-receptor-negative/human epidermal growth factor receptor 2
(HER2)-positive phenotype of primary tumor (HR = 2.6, P = 0.01), HER2 expression in BCBM (HR = 4.9, P = 0.01).
Conclusions: PD-L1 and PD-L2 expression is a common occurrence in BCBM, irrespective of primary tumor
and BCBM phenotype. Favorable prognostic impact of PD-1 expression on TILs suggests a beneficial effect of
preexisting immunity and implies a potential therapeutic role of immune checkpoint inhibitors in BCBM.
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Background
Breast cancer has not been traditionally considered an
immunogenic cancer type. However, there is an increasing
body of evidence suggesting that an effective immune re-
sponse may greatly impact on the clinical behavior of this
malignancy. Tumor lymphocyte infiltration is associated
with favorable prognosis in early triple-negative and human
epidermal growth factor receptor type 2 (HER2)-positive
breast cancer phenotypes [1–4] and may influence the
response to systemic therapies [3–6]. Information on
the association between the immune host response and
the colonization of the brain by tumor cells is scarce.
The central nervous system (CNS) has long been con-
sidered an immunologically privileged site [7]. Actually,
CNS is an immune specialized site under a tight regula-
tory control network linking microglia, astrocytes and
lymphocytes [8].
Brain metastases in preclinical and clinical models are
characterized by high proliferation, apoptosis, and inflam-
matory response in the form of surrounding extensive
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reactive gliosis [9]. It is postulated that the reactive as-
trocytes reduce apoptosis mediated by the cytotoxic
agents by sequestering calcium from the cytoplasm of
tumor cells or by secreting metastasis-stimulating che-
mokines [10]. In the inflammatory and degenerative
processes, CNS reactive glial cells actively participate in
the restimulation of T cells through the secretion of
some chemokines [9, 11, 12]. This increases the influx
of regulatory T cell (Treg) lymphocytes, resulting in si-
lencing of the immune response.
The programmed cell death protein 1 receptor (PD-1)
and its ligands, programmed cell death protein 1 recep-
tor ligand (PD-L)1 and PD-L2, also known as B7-H1 and
B7-DC, respectively, play a crucial role in the induction
and maintenance of peripheral tolerance, and protect tis-
sues from autoimmune attack [13]. The PD-1/PD-L axis
is also a key getaway pathway serving in many cancers
as an “immune control” [14, 15]. Several studies suggest
that immune response to malignant processes in the brain
may be related to the type of cancer [16–19]. Better un-
derstanding of the local immune response accompanying
brain metastases (BM) may pave the way to the develop-
ment of novel preventive and therapeutic strategies in
breast cancer patients. This retrospective study aimed to
assess the correlation between selected parameters of im-
mune response in breast cancer brain metastases (BCBM)
and their impact on overall survival.
Methods
Study population and data collection
This study was approved by the Institutional Review
Board of the coordinating center, the Military Institute
of Medicine in Warsaw, Poland. The study group included
breast cancer patients who underwent excision of BCBM
(Table 1). The patients were diagnosed and treated be-
tween 1990 and 2014 in eight oncology centers in Poland.
Demographic, clinicopathologic, and clinical follow-up
data were extracted from medical records. All data were
coded to secure full protection of personal information,
therefore, patient consent was not sought.
Pathologic analysis
The starting material from each patient was an archival
formalin-fixed, paraffin-embedded (FFPE) specimen ob-
tained at surgery from the primary breast tumor and
BCBM. The pathologic diagnosis was confirmed by a
Board-certified pathologist (RP or WB) who reviewed
FFPE tissue sections stained with hematoxylin and eosin.
A representative paraffin block from each specimen was
chosen for immunohistochemical analysis (IHC). In pa-
tients with more than one BCBM, only the single most
representative lesion was subjected to analysis.
Immunohistochemical staining
All samples were re-stained and IHC-based expression
for estrogen receptor alpha (ERα), progesterone receptor
(PR) and HER2 was determined in the central laboratory
by two pathologists (RP and WB) who were blinded to
the original assessments and to expression in the paired
samples. Then, BCBM and the adjacent brain micro-
environment were subjected to analysis of stromal tumor
infiltrating lymphocytes (TILs) (CD4+, CD8+, CTLA4+),
CD68+ cell infiltration, expression of PD-1, PD-L1, PD-L2,
and glial fibrillary acid protein (GFAP). The staining
was performed according to the manufacturers’ proto-
cols (Table 2). The TILs and CD68+ cells were scored
under a light microscope at a magnification of 400
(ocular × 10 with objective of × 40), corresponding to a
total area of 1 mm2 on full slides. As TILs are predom-
inantly present in stromal parts of BCBM and are a rare
occurrence in other BCBM compartments, we have con-
sistently used the term “stromal TILs”. TILs were consid-
ered PD-1+ if cytoplasmic staining was found in at least
1 % of cells, irrespective of staining intensity. PD-1 stain-
ing was assessed in lymphoid cells, which were identified
basing on morphologic features and previously performed
staining for/CD4+ and CD8+, with negative results (0) or
positive results (1). Due to lack of standardization criteria
of PD-L expression positivity and possible intratumoral
heterogeneity, PD1-L1 and PD-L2 were assessed in the
whole tissue sections using the semiquantitative staining
H-score, which accounts for the quantitative and qualita-
tive features of the reactions. The intensity of staining was
defined as weak (1), moderate (2), or strong (3). The inten-
sity of the reaction was determined in a percentage of
positive cells. The H-score was calculated for each bio-
marker by the formula:
3 × % Strong cellular staining (cytoplasmic, nuclear and/
or membranous) + 2 × % Moderate staining + % Weak
staining
This gave a range of 0–300. Figure 1 shows positive
control staining for PD-1, PD-L1 and PD-L2.
Statistical analysis
All statistical analyses were performed using STATA
software version 11. Statistical significance was defined
as P < 0.05. We tested correlation between parameters of
immune response in BCBM and the brain microenviron-
ment and GFAP, PD-1, PD-L1, PD-L2, TILs (CD4+, CD8+,
CTLA4+) and CD68+ cells (listed in Table 3), and assessed
their prognostic relevance. This analysis included all avail-
able clinical and pathological variables (Table 1). Due to the
retrospective and multicenter nature of the study we were
unable to include BCBM size and accompanying cerebral
edema in the analysis, or the use of steroids and diuretics.
Categorical and continuous variables were compared using
Pearson’s chi-squared test (c2), Spearman’s r rank test and
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Table 1 Patient characteristics
Variable N %












Primary tumor ERα (IHC)
Negative 42 50
Positive 42 50




























Combination thereof 14 17





For metastatic disease 4 5





For metastatic disease 5 6
Combination thereof 11 13
Unknown 2 2





Type of first progression
Regional 5 6
Distant 75 89
Local/regional and distant 3 4
Unknown 1 1
Dominant site of metastatic disease














Parietal lobe 19 23
Frontal lobe 14 17
Temporal lobe 6 7
Occipital lobe 8 10
Other 2 2
Combination thereof 6 13
Unknown 2 2
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the Mann–Whitney U test. Overall survival (OS) was
computed using the Kaplan-Meier method, starting from
BCBM excision to the date of death or the last follow up.
Univariate and multivariate analyses were performed using
the log-rank test, Wilcoxon test, and Cox proportional
hazard and logistic regression.
Results
Patient characteristics
The study group included 84 breast cancer patients who
underwent excision of BM (Table 1). Based on ERα, PR
and HER2 expression, four primary tumor phenotypes
were identified: hormone-receptor + and HER2– (23 cases),
hormone-receptor + and HER2+ (21 cases), hormone-
receptor– and HER2– (21 cases), and hormone-receptor–
and HER2+ (19 cases). Of these tumors 83 % were invasive
ductal carcinomas (no special type); 42 % were grade 2 and
46 % were grade 3: 50 % were ERα– and PR–, 48 % were
HER2+ (IHC3+ or HER2 amplified by fluorescence in situ
hybridization (FISH)). All patients underwent radical
surgery for the primary tumor; 62 % received neoadju-
vant chemotherapy and 42 % adjuvant chemotherapy,
32 % received adjuvant radiotherapy and 19 (50 % of
the 38 HER2+ cases) received adjuvant trastuzumab.
The first manifestation of progression was distant me-
tastasis in 89 % of patients, with viscera being the most
common dominant sites of metastatic disease. Forty-
seven patients (56 %) developed BM as the first site of
progression, 61 % of whom presented with a single
brain lesion at the time of excision. The mean age at
BCBM diagnosis was 53 years (range 30–81). The me-
dian length of follow up in the entire population was
61.3 months (range 8.7–209 months). The median time
to BCBM occurrence from first diagnosis of breast cancer
was 41.6 months (range 0.9–152.7). The most common
sites of BCBM were the cerebellum and parietal lobe.
After BCBM excision, 75 % of patients were administered
whole brain radiotherapy, 44 % received chemotherapy
and 18 % endocrine therapy. Eight HER2+ patients re-
ceived trastuzumab or lapatinib. The median OS after
BCBM excision was 18.3 months (range 0–99 months).
Lymphocyte subpopulations, microglia/macrophages and
reactive astrocyte infiltration in the brain
microenvironment
TIL (CD4+, CD8+) and macrophage/microglia (CD68+)
infiltration was determined in 96 %, 98 % and 92 % of
Table 1 Patient characteristics (Continued)
















Lapatinib after BCBM excision in HER2+ primary breast cancer
No 14 17
Yes 8 10
Alive at last follow up
No 75 89
Yes 9 11
Age at breast cancer diagnosis; mean (range) years 49 (28–80)
Age at BCBM diagnosis; mean (range) years 53 (30–81)
Percentages for values of patient characteristics may not sum to 100 because
of rounding to full numbers. N number, ERα estrogen receptor alpha, PR
progesterone receptor, IHC immunohistochemical analysis, FISH fluorescence
in situ hybridization, HR hormone receptor, HER2 human epidermal growth
factor receptor 2, BCBM breast cancer brain metastases
Table 2 Antibodies, dilutions and methods of evaluation
Target Manufacturer Catalog number (type of staining) Dilution Incubation time Control tissue Method of evaluation
PD-1 Novus NBP1-88104 (cytoplasmic) 1:100 30’ min LN SQ
PD-L1 AbD Serotec AHP2128 (membranous/cytoplasmic) 1:50 40’ min HSM SQ
PD-L2 R&D systems AF1224 (membranous/cytoplasmic) 1:500 30’ min LN SQ
CTLA4 Santa Cruz SC-376016 (cytoplasmic) 1:50 40’ min LN SQ
GFAP Dako M0761 (cytoplasmic) RU 30’ min B SQ
CD4 Dako IR649 (membranous) RU 20’ min LN Q
CD8 Dako IR623 (cytoplasmic and membranous) RU 20’ min LN Q
CD68 Dako IR609 (cytoplasmic) RU 20’ min LN Q
RU ready to use, SQ semiquantitative, Q quantitative, HSM human skeletal muscle, LN lymph node, B brain, PD-1 programmed death-1 receptor, PD-L1 PD-1 ligand 1,
PD-L2 PD-L2 ligand 2, CTLA4 cytotoxic T cell antigen 4, GFAP glial fibrillary acid protein
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cases, respectively (Table 3). TILs were identified in both
stromal and epithelial compartments of BCBM, but were
generally much more abundant in the stroma (Fig. 2a,
b). There was no CTLA4 expression on TILs (Fig. 2c).
The median number (per mm2) of CD4+ TILs was 49
(interquartile range (IQR) 23–121), of CD8+ TILs was 69
(IQR 38–127), and of CD68+ TILs was 76 (IQR 57–104)
(Table 3). CD4+ and CD8+ TILs were positively correlated
(r = 0.48; P < 0.001) and both were positively correlated with
CD68+ cells (r = 0.23; P = 0.043 and r = 0.27, P = 0.019,
respectively) (Table 4). GFAP, a biomarker of reactive astro-
cytes, was expressed in 71 % of cases (Table 3). There
was no correlation between GFAP expression and BCBM
phenotype, TILs and CD68+ cell infiltration, or expression
of PD-1 and its ligands.
PD-1 expression on TILs and PD-L1, PD-L2 expression in
BCBM
PD-1 expression on TILs in BCBM was identified in 17
cases (23 %), more frequently in older patients (mean
age at brain metastasis diagnosis in PD-1+ and PD-1–
groups 59 and 51 years, respectively; P = 0.003), and in
cases with HER2-amplified primary breast cancer. PD-1
expression was correlated positively with both TILs:
CD4+ (r = 0.26; P = 0.028) and CD8+ (r = 0.33; P = 0.005;
Table 4). PD-1+ patients, compared to PD-1– patients
had longer OS after BCBM excision (median 27.9 months
(range 0.1–88.9) vs. 13.9 months (0.0–82.6), respectively;
P = 0.02) (Fig. 3a and Table 5). There was no correlation
between expression of PD-1 on TILs and PD-1 ligands
in BCBM (Table 4). PD-L1 and PD-L2 expression in
BCBM was present in 41 (53 %) and 28 (36 %) cases, re-
spectively, and was not related to BCBM phenotype. The
mean expression for PD-L1 and PD-L2 (H-score) was 27
and 26, respectively (Table 3).
Clinical outcomes
There was no impact of previous systemic adjuvant ther-
apy including trastuzumab on the analyzed immunological
parameters in the brain. In HER2+ patients, the adminis-
tration of trastuzumab before BCBM development did not
affect CD4+ (P = 0.77) or CD8+ TILs (P = 0.17), CD68+
Fig. 1 Immunohistochemical positive control (original magnification × 400). a Programmed cell death protein 1 receptor (PD-1): lymph node
(germinal center in follicle). b Programmed cell death protein 1 receptor ligand (PD-L1): skeletal muscle. c PD-L2: lymph node (subcapsular sinus)
Table 3 Assessment of selected parameters of immune
response in breast cancer brain metastasis and the brain
microenvironment
Variable Number %
Reactive astrocytes (glial fibrillary acid protein expression) 83/84 99
No 15 18
Yes 60 71
No neuronal tissue 8 10
Stromal tumor infiltrating lymphocytesa (CD4+) 81/84 96
Median 49
IQR 23–121
Stromal tumor infiltrating lymphocytesa (CD8+) 82/84 98
Median 69
IQR 38–127
Microglia/macrophagesa (CD68+) 77/84 92
Median 76
IQR 57–104
PD-1 expression on tumor infiltrating lymphocytes 74/84 88
No 57 68
Yes 17 20
Not determined 10 12
PD-L1 expression on BCBM 78/84 93
H-score; mean (range) 27.1 (0–200)
PD-L2 expression on BCBM 78/84 93
IQR interquartile range, PD-1 programmed cell death protein 1 receptor,
PD-L1 programmed cell death protein 1 receptor ligand 1, PD-L2 programmed
cell death protein 1 receptor ligand 2, BCBM breast cancer brain metastases.
aDensity was scored at magnification × 400 (ocular × 10 with an objective × 40
high-power field (HPF) per 1 mm2
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infiltration (P = 0.77), or expression of PD-1 (P = 0.85),
PD-L1 (P = 0.86), or PD-L2 (P = 0.80). The univariate ana-
lysis of survival included all available clinicopathologic
variables (the histology, grade and expression of ER, PR
and HER2 in the primary tumor, phenotype of the primary
tumor and BCBM, treatments administered prior to and
after BCBM, type of first progression, dominant metastatic
site and location of BCBM) and all studied immune
parameters (reactive astrocytes (GFAP), TILs (CD4+, CD8,
microglia/macrophages (CD68+), PD-1 expression on TILs,
and PD-L1 and PD-L2 expression on BCBM). The
multivariate analysis included variables that were significant
Fig. 2 Immunohistochemical analysis (original magnification × 200). a CD4+ lymphocytes. b CD8+ lymphocytes. c CTLA4– lymphocytes. d CD68+
cells. e Glial fibrillary acid protein (GFAP) weak positive-reactive astrocytes. f GFAP moderate positive-reactive astrocytes. g Programmed cell death
protein 1 receptor (PD-1)-negative expression on stromal tumor infiltrating lymphocytes (TILs) in the brain microenvironment. h PD-1-positive
expression on TILs in the brain microenvironment. i PD-L1 negative expression on TILs in brain microenvironment. j Programmed cell death
protein 1 receptor ligand (PD-L1)-negative expression in breast cancer brain metastases (BCBM). k PD-L1 weak positive expression in BCBM.
l PD-L1 moderate positive expression in BCBM. m PD-L2 negative expression in TILs in the brain microenvironment. n PD-L2 negative expression in
BCBM. o PD-L2 weak positive expression in BCBM. p PD-L2 moderate positive expression in BCBM
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(P < 0.05) in the univariate analysis (Table 5). In this ana-
lysis, favorable factors for survival after BCBM excision in-
cluded PD-1 expression on TILs (hazard ratio (HR) = 0.3
(0.1–0.7); P = 0.003) (Fig. 3a) and CD68+ cell infiltration
(HR = 0.2 (0.1–0.5); P < 0.001) (Fig. 3b), brain radiotherapy
(HR = 0.1 (0.1–0.3); P < 0.001), and endocrine therapy after
the development of BCBM (HR= 0.1 (0.1–0.3) P < 0.001;
Table 5). Adverse prognostic factors included a hormone
receptor–/HER2+ primary tumor phenotype (HR = 2.6
(1.3–5.5); P = 0.01) and HER2 expression in BCBM (HR =
4.9 (1.3–19.2); P = 0.01).
Discussion
We have presented a comprehensive analysis of several
immune parameters in BCBM. This is also the largest
study analyzing the clinical relevance of these parame-
ters. Our data indicate that the PD-1/PD-L axis may play
an important role in the local immune response accom-
panying BCBM. Furthermore, we observed that the infil-
tration of the brain microenvironment by CD4+ and
CD8+ lymphocytes, macrophages/microglia and reactive
astrocytes is a common occurrence, and these features
are probably independent of BCBM phenotype and pre-
vious systemic therapies.
There are two leading hypotheses explaining PD-L1
expression in tumors: the first based on the innative, and
the second on the adaptive model [20]. In the innative
model, PD-L1 expression is independent of the tumor
microenvironment and is influenced by intrinsic cell
Table 4 Spearman’s correlation (r) for continuous variables
Variable CD4 CD8 CD68 PD-L1 PD-L2
CD4 r – 0.48 0.23 0.12 0.20
P <0.001 0.043 0.311 0.088
CD8 r 0.48 – 0.27 0.13 0.19
P <0.001 0.019 0.264 0.100
CD68 r 0.23 0.27 – 0.09 0.19
P 0.043 0.019 0.471 0.104
PD-L1 r 0.12 0.13 0.09 – 0.12
P 0.311 0.264 0.471 0.317
PD-L2 r 0.20 0.19 0.19 0.12 –
P 0.088 0.100 0.104 0.317
PD-1a r 0.26 0.33 0.06 −0.04 0.13
P 0.028 0.005 0.617 0.742 0.267
PD-1 programmed cell death protein 1 receptor, PD-L1 programmed cell death
protein 1 receptor ligand. aCategorical variable
Fig. 3 Kaplan-Meier curves for overall survival (OS) after excision of breast cancer bone metastases (BM). a Programmed cell death protein 1
receptor (PD-1)-positive vs. PD-1-negative stromal tumor infiltrating lymphocytes (TILs) in the brain microenvironment. b high vs. low
macrophage/microglia infiltration (CD68+) in the brain microenvironment. HR hazard ratio
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signaling pathways. The adaptive model assumes that
TILs are the key factor driving PD-L1 expression and
that immune resistance is exerted by tumor cells in re-
sponse to endogenous antitumor activity [13, 21–23].
This allows tumor cells to escape immune destruction
despite endogenous antitumor immune reactions. Previ-
ous studies showed that the PD-1/PD-L axis regulates the
induction and maintenance of peripheral tolerance and
protects tissues from autoimmune attack (reviewed by Jin
et al. [23]). PD-L1 expression in the CNS was identified in
glioblastoma and in human brain metastases from melan-
oma, renal cell carcinoma, lung cancer, colon cancer, and
breast cancer, and the PD-1/PD-L1 axis in primary brain
lymphomas [16–19]. Here, we demonstrated that PD-L1
and PD-L2 expression is also a common occurrence in
BCBM, irrespective of the primary tumor and brain
metastasis phenotype.
Recently, PD-L1 expression was found to be more
common in primary triple-negative breast cancer [24, 25],
but we did not find such a correlation in BCBM. However,
PD-L1 expression is a dynamic process in normal condi-
tions and is influenced by cytokines, such as interferon
(INF)-γ [26]. In turn, PD-L1 expression in tumor cells may
be influenced by systemic therapy. Moreover, biopsy timinig
(at diagnosis vs. at progression) to determine PD-L1 expres-
sion may be critical in patient selection for immune check-
point inhibitors or other experimental therapies [27].
Hitherto, there are no data on the comparison of PD-L ex-
pression in primary breast cancer and in the corresponding
BCBM. In a recent study by Berghoff et al. [28] there was
no correlation between PD-L1 expression in brain metasta-
ses from various solid tumors and TIL density, and the au-
thors also postulated that the density of CD3+, CD8+ and
CD45RO+ TILs, and the calculated immunoscore, are posi-
tively correlated with survival. In the recent study by Harter
et al. [19], which included several tumor types, there was
no significant prognostic impact of TIL expression in brain
metastases in the entire population, and there was a strong
trend towards better survival in brain metastases from mel-
anoma with high levels of PD-L1 [19].
The biological role of PD-L2 is less well-understood.
Recent studies showed that PD-L2 can be induced on
antigen-presenting cells, such as macrophages, dendritic
cells, T cells and a wide variety of non-immune cells, de-
pending on the microenvironmental stimuli [29]. Some
studies suggest an adverse prognostic impact of PD-L
expression, whereas others, including ours, did not find
such a relationship, or even showed the opposite [18, 19,
30, 31]. These differences may likely be due to different
methods used for the detection of ligand expression and
the lack of standardized criteria for assessment of PD-L
expression.
PD-1 is an inhibitory co-receptor expressed on acti-
vated and exhausted T cells [13–15, 32, 33]. We demon-
strated that PD-1 expression on TILs in BCBM is
independently associated with increased OS. However,
our study included patients with limited numbers of
BCBM eligible for resection and with good performance
status, and most had controlled extracranial disease.
Hence it is unknown whether this observation applies to
all patients with BCBM. Although PD-1 expression cor-
related with CD4+ and CD8+ TILs, increased OS was
not directly related to the mere presence of TILs, an ob-
servation suggesting the importance of preexisting active
immunity. Interestingly, in the abovementioned study by
Harter et al. [19], PD-1+ lymphocytes and the ratio be-
tween PD-1 and CD8+ cells were higher in smaller than
in larger metastases. This finding may indicate that in
smaller metastases the lymphocytic immune response is
activated but functionally impaired. It is also possible
that T cells may control the tumor size transiently before
becoming exhausted.
Data on the prognostic value of PD-1 expression on
TILs in various malignancies are scarce and inconsistent.
In primary renal cell carcinoma, on univariate analysis
PD-1 expression on mononuclear immune cell infiltrates
was found to increase the risk of cancer-specific death and
overall mortality [34]. However, in this study PD-1 was as-
sociated with more advanced disease, the presence of co-
agulation, tumor necrosis, and sarcomatoid differentiation.
Table 5 Factors impacting overall survival after excision of breast cancer brain metastases (significant in univariate and multivariate
analysis)
Variable Univariate analysis Multivariate analysis
HR (95 % CI) P HR (95 % CI) P
Primary tumor phenotype HER2-enriched, yes vs. no 3.0 (1.1–9.9) 0.033 2.6 (1.3–5.5) 0.010
Radiotherapy after BCBM, yes vs. no 0.1 (0.0–0.2) <0.001 0.1 (0.1–0.3) <0.001
Endocrine therapy after BCBM excision, yes vs. no 0.1 (0.0–0.2) <0.001 0.1 (0.0–0.3) <0.001
HER2 IHC expression in BCBM, yes vs. no 6.5 (1.5–27.8) 0.011 4.9 (1.3–19.2) 0.020
PD-1 expression on TILs in brain, yes vs. no 0.5 (0.3–0.9) 0.015 0.3 (0.1–0.7) 0.003
Microglia/macrophages infiltration, ≥104 vs. <104 per mm2 0.6 (0.3–1.0) 0.049 0.2 (0.1–0.5) <0.001
HR hazard ratio, HER2 human epidermal growth factor receptor 2, BCBM breast cancer brain metastases, IHC immunohistochemical analysis TILs stromal
tumor-infiltrating lymphocytes, PD-1 programmed death receptor type 1
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Hence, this feature may be associated with more aggressive
disease characteristics rather than be an adverse prognostic
factor per se. Similarly, in operable breast cancer, PD-1+
immune cell infiltration in the primary tumor is reported to
correlate with shorter survival [35]. In contrast to these re-
ports, in a series of recent studies the PD-1/PD-L1 axis had
a favorable effect, supporting the role of preexisting antitu-
mor immunity [5, 36, 37]. Notably, all these studies relate
to primary tumors, whereas we included BCBM, in which
immune mechanisms may be substantially different due to
the immune privilege of the CNS [7, 37]. Nonetheless,
evidence of a favorable prognostic role of PD-1 expres-
sion on TILs in BCBM should be considered cautiously
and warrants confirmation.
We did not observe a relationship between expression
of PD-1 on TILs, and PD-Ls expression in BCBM, and
neither did we find major differences across breast cancer
phenotypes, except for more common PD-1 expression in
HER2-amplified primary tumors. According to the adap-
tive resistance hypothesis, cancer cells can upregulate the
expression of PD-L1 after encountering T cells, mostly via
IFN-γ. However, there are data suggesting that cancer cells
also express PD-L1 by an intrinsic, INF-γ independent
mechanism [38, 39]. Further, some genetic abnormalities,
such as a loss of phosphatase and tensin homolog in
glioma or triple-negative breast cancer, and epidermal
growth factor receptor mutations in lung cancer, can
directly upregulate PD-L1 on cancer cells [24, 40, 41].
On the other hand, it has been speculated that the local
CNS microenviroment may in some way suppress the
INF-γ mediated response, thus, paradoxically decreasing
brain tissue damage [37]. Interestingly, only an undeter-
mined fraction of lymphocyte infiltration dies through the
interaction with the PD-1/PD-L axis. Additionally, there
are non-PD-1 costimulatory receptors for PD-L, which are
responsible for the enhanced effector function of PD-L-
expressing tumor cells [42, 43].
In this series, besides PD-1 expression, macrophages/
microglia infiltration was also found to be associated with
significantly longer survival after the excision of BCBM.
The macrophages/microglia play a key role in the develop-
ment of innate and adaptive immune response in the brain
[44]. These cells are perceived as a main source of proin-
flammatory cytokines and more as antigen-presenting cells,
and actively participate in the T cell restimulation [8, 9, 44].
The limitation of our study was identifying macrophages/
microglia exclusively by CD68 staining, as other markers
(such as CD14, CD11b, and/or MHC-II) might have likely
provided more data on the prognostic role of these cells.
Some preclinical studies suggest a potential role for
immune checkpoint inhibitors in mammary tumors, par-
ticularly HER2+ phenotypes. Combining trastuzumab
with inhibitors of negative T cell regulation, such as anti-
PD-1, anti-PD-L1 or anti-CTLA4 antibodies, may increase
antitumor efficacy [45, 46]. In HER2+ patients receiving
trastuzumab, PD-1 inhibition stimulates CD8+ cells
producing INF-γ, and may increase the therapeutic effect of
this antibody [46]. However, in our study trastuzumab ad-
ministered before the development of BCBM did not affect
the expression of TILs, CD68+ cell infiltration, or PD-1 and
its ligands in BCBM. The brain microenvironment may
promote HER2 expression via secretion of specific cyto-
kines, such as neuregulin [47]. We recently demonstrated
that expression of quantitative HER2 and p95 - its trun-
cated, constitutively active form - is significantly increased
in BCBM compared to primary breast cancers [48]. In that
study, p95 expression in brain metastases also correlated
with poorer clinical outcome.
Currently, PD-1 inhibitors, such as pembrolizumab
and nivolumab, are a subject of clinical investigation in
non-small cell lung cancer and melanoma with brain
metastases (NCT02085070, NCT02320058), whereas no
data are available for anti-PD therapies in BCBM. Hence,
there is a rationale for investigation into boosting the
host antitumor immune response by inhibiting the in-
hibitors (via increasing lymphocyte influx to the brain
or inhibiting PD-L expression in tumor cells) also in
BCBM. Pembrolizumab has shown promising effects
and a good safety profile in PD-L1-positive advanced
triple-negative breast cancer (KEYNOTE-012 study;
NCT01848834) and in heavily pretreated ER+/HER2–
breast cancer (KEYNOTE-028 study; NCT02054806)
[49, 50]. PD-L1 inhibitors, atezolizumab (MPDL3280A)
and avelumab (MSB0010718C) appear to be particularly
active in triple-negative breast cancer [51, 52]. Several
ongoing clinical trials are investigating other immune
checkpoint inhibitors in both in locally advanced and/
or metastatic breast cancer and in the adjuvant setting
(reviewed in Chawla et al. [53]).
Conclusions
We demonstrated an important role for an activated
preexisting immune response in a relatively large group
of patients with BCBM. However, we are aware of some
limitations of this study, including its retrospective na-
ture, small number of cases in particular subsets, and
the lack of assay standardization in terms of sampling
and other technical issues. Thus, our findings warrant
confirmation in further investigations.
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